Immunome (IMNM) Profit After Tax (2019 - 2026)

Immunome (IMNM) has 8 years of Profit After Tax data on file, last reported at -$53.8 million in Q1 2026.

• Quarterly Profit After Tax fell 29.3% year-over-year to -$53.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$224.6 million (down 9.5% YoY) and the FY2025 annual result came in at -$212.4 million, up 27.5% from the prior year.
• Profit After Tax advanced to -$53.8 million in Q1 2026, from -$69.9 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$4.3 million in Q1 2023 to a low of -$129.5 million in Q1 2024.
• A 5-year average of -$41.4 million and a median of -$41.6 million in 2025 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2024 — Profit After Tax slumped 2932.6% — and 2025, when it jumped 67.84%.
• Tracing IMNM's Profit After Tax over 5 years: stood at -$8.4 million in 2022, then sank by 1000.43% to -$92.6 million in 2023, then rose by 13.37% to -$80.2 million in 2024, then rose by 12.9% to -$69.9 million in 2025, then grew by 22.98% to -$53.8 million in 2026.
• The last three Profit After Tax figures came in at -$53.8 million (Q1 2026), -$69.9 million (Q4 2025), and -$57.5 million (Q3 2025), per Business Quant data.